Pfizer hosted a discussion with sell-side analysts to provide an update on one of the vaccine pipeline items – a second-generation Clostridioides difficile (C. diff) vaccine effort in Phase 2.Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Pfizer, Inc PFE with a price target of $33.Shibutani recalled that Pfizer had reported negative results from a Phase 3 study for a first-generation asset in March 2022, where the primary endpoint was unmet.Also Read: Elon Musk’s xAI To Expand With New Cha ...

As an investor in Pfizer (NYSE: PFE ), one of the world's largest pharmaceutical companies, I am marginally disappointed, as other investors would be, that the company had another underwhelming year on the stock markets.Uttam is a growth-oriented investment analyst whose equity research primarily focuses on the technology sector. Semiconductors, Artificial Intelligence and Cloud software are some of the key sectors that are regularly researched and published by him. His research also focuses on other areas ...

Stuart Therapeutics adds recognized leaders in ophthalmology therapeutics development, commercialization.STUART, Fla., Dec. 22, 2024 /PRNewswire/ -- Stuart Therapeutics announced today the appointment of Tracy Valorie and Jason Werner to the company's Board of Directors, bringing the total number of Board members to five. These new Directors will hold the positions previously held by Robert O. Baratta, MD, who passed away suddenly in the third quarter of this year, and retired US Representative Diane Black, ...

Amid a fall season characterized by restive shareholders seeking an activist bid to unseat senior management and change the trajectory of the company, Pfizer (PFE 2.29%) is communicating that everything is under control. Per its updated forecast for its 2024 and 2025 fiscal years on Dec. 17, the overarching message is that the pharma will continue to seek to control its costs while bolstering its portfolio of medicines as usual.But does that make the stock a buy, or is there reason to be cautious? Let's dig ...

In the latest market close, Pfizer (PFE) reached $25.77, with a -0.46% movement compared to the previous day. This change lagged the S&P 500's 0.09% loss on the day. Meanwhile, the Dow experienced a rise of 0.04%, and the technology-dominated Nasdaq saw a decrease of 0.1%.The the stock of drugmaker has risen by 3.81% in the past month, leading the Medical sector's loss of 2.1% and the S&P 500's loss of 0.29%.Analysts and investors alike will be keeping a close eye on the performance of Pfizer in its upcomin ...

Shares of Pfizer (PFE -2.04%) recently marched higher in response to a dividend payout raise and a forward-looking presentation. Management confirmed the annual revenue and earnings outlook it provided in October and issued guidance for the year ahead.In response to Pfizer's latest guidance update, BMO Capital analyst Evan Seigerman reiterated an outperform rating and a $36 per-share price target. If Pfizer stock reaches Seigerman's target, investors who buy at recent prices could see their principal invest ...

The major pharmaceutical maker Pfizer Inc. (NYSE: PFE ) recently reported its 2025 guidance on December 17 th, so I thought I would take another look at PFE from the technical analysis approach. My most recent article aboutAs an individual investor nearing retirement I am trying to build my financial assets in order to have a fulfilling retirement. I am interested in trading both long and short; or at least using inverse ETFs, to take advantage of market declines. Having long term and short term trading str ...

Pfizer's (PFE) stock rose almost 5% on Tuesday after it announced an encouraging guidance for 2025.Pfizer projected total revenues between $61.0 billion and $64.0 billion. The Zacks Consensus Estimate for the metric is pegged at $62.86 billion. Adjusted earnings are expected in the range of $2.80 to $3.00. The Zacks Consensus Estimate is pegged at $2.90 per share.The company’s sales and earnings projections for 2025 were within investor expectations. Many analysts believe the guidance is achievable.Pfizer a ...

CHINA - 2024/09/21: In this photo illustration, a Pfizer logo is displayed on the screen of a ... [+] smartphone. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesPfizer stock (NYSE: PFE) was up 5% on Tuesday, December 17, after the company announced an optimistic outlook for 2025. The company expects its revenue to be in the range of $61 billion to $64 billion, and its adjusted earnings to be in the range of $2.80 and $3.00 per share. Th ...

Pfizer (NYSE: PFE) shares rose nearly 3% to $25.98 in premarket trading on December 17 after the pharmaceutical giant released its 2025 financial guidance. While the outlook painted a mixed picture, investor sentiment leaned positive, driven by an optimistic earnings forecast that signals progress in Pfizer’s ongoing turnaround efforts.At press time, Pfizer stock was trading at $26.30, marking a 2.7% gain for the day, with the monthly chart showing a 3% increase. Despite these gains, Pfizer remains down 11% ...